Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III tri (Q54350050)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III tri	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III tri (English)

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

George Fountzilas

23

object named as

G Fountzilas

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

author name string

P Skarlos

1

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

C Christodoulou

2

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

K T Kalogeras

3

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

A G Eleftheraki

4

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

A Batistatou

6

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

C Valavanis

7

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

O Tzaida

8

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

E Timotheadou

9

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

R Kronenwett

10

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

R M Wirtz

11

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

I Kostopoulos

12

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

D Televantou

13

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

E Koutselini

14

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

I Papaspirou

15

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

C A Papadimitriou

16

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

D Pectasides

17

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

H Gogas

18

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

G Aravantinos

19

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

N Pavlidis

20

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

P Arapantoni

21

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

D V Skarlos

22

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

publication date

8 September 2011

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

69

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

2

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

533-546

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

https://scigraph.springernature.com/pub.10.1007/s00280-011-1730-9

0 references

RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Management of breast cancer with targeted agents: importance of heterogeneity. [corrected].

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Role of anthracyclines in the treatment of early breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Tissue microarrays for high-throughput molecular profiling of tumor specimens

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Supervised risk predictor of breast cancer based on intrinsic subtypes

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Prognostic markers in triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Use of archived specimens in evaluation of prognostic and predictive biomarkers

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1730-9

21 January 2018

Identifiers

10.1007/S00280-011-1730-9

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

1 reference

Europe PubMed Central

28 May 2018

http://europepmc.org/abstract/MED/21901395

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54350050&oldid=1245986600"